Angelini Pharma completes $4.1 billion Catalyst acquisition, secures €2 billion backing

The deal gives Angelini Pharma Catalyst’s portfolio and U.S. commercial infrastructure, while Blackstone and CDP Equity support the group’s push in brain health and rare diseases.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.